All In MedTech

Device Trial Radar · NCT07214532

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

SIgnatera-Guided Initiation of Adjuvant CDK4/6 Inhibitor in Intermediate Risk HR+ HER2- Breast Cancer

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

725

Planned (sponsor's estimate)

Start

May 8, 2026

Primary completion

May 15, 2032

Study completion Dec 30, 2037

Sponsor

Lead sponsor
Natera, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Oct 9, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of ctDNA-guided initiation of CDK4/6 inhibitor therapy using the Signatera™ Designed on Genome test (referred to as "Signatera Genome") in participants with intermediate-risk HR+/HER2- early-stage breast cancer. Based on ctDNA test results, participants will either start CDK4/6 inhibitor therapy in addition to hormone therapy or continue hormone therapy with ongoing ctDNA surveillance. This study will compare outcomes to historical controls from the NataLEE trial to determine whether ctDNA-guided timing maintains efficacy while reducing unnecessary treatment. Participants will be followed for up to 9 years with regular blood draws, hormone therapy, imaging as needed, and quality-of-life assessments.

Conditions

  • Breast Neoplasms
  • Carcinoma, Ductal, Breast
  • Receptors, Estrogen (for ER-positive Requirement)

Interventions

  • ctDNA-Guided Treatment StrategyDevice

    Circulating tumor DNA testing using Signatera Genome assay is performed every 3 months for up to 4 years to guide timing of CDK4/6 inhibitor initiation. Participants with positive ctDNA results initiate CDK4/6 inhibitor therapy (ribociclib or abemaciclib) plus standard endocrine therapy for a minimum of 2 years. Participants with negative ctDNA results continue endocrine therapy alone with ongoing surveillance. CDK4/6 inhibitor selection and endocrine therapy regimen per the physician's choice following standard-of-care guidelines.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive Disease-Free SurvivalTime frame: From the date of surgery up to 9 years

Locations

50 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona · Not yet recruiting

  • Honor Health Research Institute

    Scottsdale, Arizona · Not yet recruiting

  • University of Arizona Cancer Center

    Tucson, Arizona · Not yet recruiting

47 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.